- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 06.02. | Orchestra BioMed Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.01. | Orchestra BioMed to pick up $21M through Haemonetics' acquisition of Vivasure | 2 | MassDevice | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 12.01. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Assessing Orchestra BioMed Holdings: Insights From 4 Financial Analysts | 1 | Benzinga.com | ||
| 10.12.25 | TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio | 1 | Investing.com | ||
| 08.12.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting | 156 | GlobeNewswire (Europe) | Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension... ► Artikel lesen | |
| 26.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.11.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.25 | Orchestra BioMed Holdings Q3 Loss Widens | 1 | RTTNews | ||
| 10.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | 202 | GlobeNewswire (Europe) | Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital... ► Artikel lesen | |
| 10.11.25 | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | Orchestra BioMed files secondary offering of ~8M shares | 2 | Seeking Alpha | ||
| 28.10.25 | Orchestra BioMed, Terumo Sign $30 Million Strategic Agreements For Virtue SAB | 5 | RTTNews | ||
| 28.10.25 | Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement | 2 | MassDevice | ||
| 28.10.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10.25 | Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial | 1 | MassDevice | ||
| 27.10.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial | 272 | GlobeNewswire (Europe) | Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release... ► Artikel lesen | |
| 09.10.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 56,12 | -21,67 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen | |
| ARCELLX | 68,50 | -0,22 % | Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns | ||
| QIAGEN | 43,280 | +1,00 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,88 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| UPSTREAM BIO | 8,740 | -31,72 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,78 | -3,91 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ZENAS BIOPHARMA | 26,520 | +1,57 % | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | ||
| EVOTEC | 6,186 | +6,18 % | Bayer, Evotec oder Novo Nordisk: Dieser Biotech setzt zum Sprung an! | Seit Jahren schlagen unsere Aktien-Profis regelmäßig den Gesamtmarkt und sorgen für steile Renditen in den Anlegerdepots. So auch mit den Aktien von Bayer, Evotec oder Novo Nordisk. Doch unser Top-Favorit... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 67,74 | -2,27 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 317,31 | -4,69 % | Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,930 | +3,71 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| ERASCA | 12,020 | -2,36 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| MINERALYS THERAPEUTICS | 27,600 | -0,93 % | Mineralys Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TANGO THERAPEUTICS | 12,900 | +1,82 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+0,52 %) liegt der Kurs bei 3,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.